OBJECTIVES: Morbidity from GI symptoms in diabetes is considered to be high, but no studies have quantified the impact of GI symptoms in diabetes on health-related quality of life. We hypothesized that diabetics reporting increased GI symptoms would experience more impaired quality of life. METHODS: Subjects from the community with diabetes (n = 892) and outpatients with diabetes (n = 209) were recruited for this study. Subjects were divided into type 1 (diabetes diagnosed at age <30 yr and requiring insulin) and type 2. A validated questionnaire measuring GI symptoms and diabetes status and the Short Form-36 were completed. The results were compared with Australian normal data. GI symptom groups measured were frequent abdominal pain, bowel-related abdominal pain, reflux, dyspepsia, constipation, diarrhea, and fecal incontinence. RESULTS: There was a clinically significant decrease in quality-of-life scores in diabetics compared with population norms across all subscales. The impact on quality of life in diabetes was predominantly observed in type 2 diabetics. The quality-of-life scores in all subscales decreased markedly with increasing numbers of distinct GI symptom groups, and this was similar in community and outpatient diabetics. For all the Short Form-36 subscales, GI symptom groups were significantly (all p < 0.0001) associated with poorer quality of life in diabetes, independent of age, gender, smoking, alcohol use, and type of diabetes. CONCLUSIONS: GI symptoms impact negatively on health-related quality of life in diabetes mellitus.
OBJECTIVES: Morbidity from GI symptoms in diabetes is considered to be high, but no studies have quantified the impact of GI symptoms in diabetes on health-related quality of life. We hypothesized that diabetics reporting increased GI symptoms would experience more impaired quality of life. METHODS: Subjects from the community with diabetes (n = 892) and outpatients with diabetes (n = 209) were recruited for this study. Subjects were divided into type 1 (diabetes diagnosed at age <30 yr and requiring insulin) and type 2. A validated questionnaire measuring GI symptoms and diabetes status and the Short Form-36 were completed. The results were compared with Australian normal data. GI symptom groups measured were frequent abdominal pain, bowel-related abdominal pain, reflux, dyspepsia, constipation, diarrhea, and fecal incontinence. RESULTS: There was a clinically significant decrease in quality-of-life scores in diabetics compared with population norms across all subscales. The impact on quality of life in diabetes was predominantly observed in type 2 diabetics. The quality-of-life scores in all subscales decreased markedly with increasing numbers of distinct GI symptom groups, and this was similar in community and outpatientdiabetics. For all the Short Form-36 subscales, GI symptom groups were significantly (all p < 0.0001) associated with poorer quality of life in diabetes, independent of age, gender, smoking, alcohol use, and type of diabetes. CONCLUSIONS: GI symptoms impact negatively on health-related quality of life in diabetes mellitus.
Authors: Kyoung Moo Choi; Purna C Kashyap; Nirjhar Dutta; Gary J Stoltz; Tamas Ordog; Terez Shea Donohue; Anthony J Bauer; David R Linden; Joseph H Szurszewski; Simon J Gibbons; Gianrico Farrugia Journal: Gastroenterology Date: 2010-02-20 Impact factor: 22.682
Authors: H P Parkman; M Camilleri; G Farrugia; R W McCallum; A E Bharucha; E A Mayer; J F Tack; R Spiller; M Horowitz; A I Vinik; J J Galligan; P J Pasricha; B Kuo; L A Szarka; L Marciani; K Jones; C R Parrish; P Sandroni; T Abell; T Ordog; W Hasler; K L Koch; K Sanders; N J Norton; F Hamilton Journal: Neurogastroenterol Motil Date: 2009-12-09 Impact factor: 3.598
Authors: Jennifer Christie; Sagar Shroff; Nikrad Shahnavaz; Latoya A Carter; Melanie S Harrison; Karan A Dietz-Lindo; John Hanfelt; Shanthi Srinivasan Journal: Am J Gastroenterol Date: 2016-12-06 Impact factor: 10.864
Authors: Francesca D'Addio; Stefano La Rosa; Anna Maestroni; Peter Jung; Elena Orsenigo; Moufida Ben Nasr; Sara Tezza; Roberto Bassi; Giovanna Finzi; Alessandro Marando; Andrea Vergani; Roberto Frego; Luca Albarello; Annapaola Andolfo; Roberta Manuguerra; Edi Viale; Carlo Staudacher; Domenico Corradi; Eduard Batlle; David Breault; Antonio Secchi; Franco Folli; Paolo Fiorina Journal: Cell Stem Cell Date: 2015-10-01 Impact factor: 24.633
Authors: Pierre Annede; Caroline Prieux-Klotz; Thomas Dubergé; Cyrus Chargari; Olivier Gisserot; Jean-Pierre de Jaureguiberry Journal: J Gastrointest Oncol Date: 2017-08